← Back to Search

Vitamin B3 Supplement

Randomized Crossover for Cognitive Decline

N/A
Waitlist Available
Led By Steven Arnold, MD
Research Sponsored by Steven E Arnold, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial will test whether Niagen, a supplement containing Vitamin B3, can improve cognitive function, mood, and daily activity in people with Subjective Cognitive Decline or Mild Cognitive Impairment.

Eligible Conditions
  • Cognitive Decline
  • Mild Cognitive Impairment

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The effect of Niagen vs PBO on RBANS.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Randomized CrossoverExperimental Treatment1 Intervention
The primary outcome of this study will be objective measures of cognitive performance measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at baseline, crossover, and the end of study. Subjects will receive 1200 mg Niagen and PBO dispensed in randomized blocks. All subjects will receive both.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Niagen
2020
Completed Phase 4
~170

Find a Location

Who is running the clinical trial?

Steven E Arnold, MDLead Sponsor
1 Previous Clinical Trials
15 Total Patients Enrolled
Steven E ArnoldLead Sponsor
1 Previous Clinical Trials
15 Total Patients Enrolled
Steven Arnold, MDPrincipal InvestigatorMGH
1 Previous Clinical Trials
15 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment
Steven E Arnold, MD 2020. "Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04078178.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top